Dual-Pathway Inhibitory Dysfunction in Schizophrenia: MEG and Behavioral Markers for Risk Stratification
Journal of Psychiatry and Neuroscience · 2026
DOI: 10.1139/jpn-25-0109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychiatry and Neuroscience, 2026. Verfasst von Yinglin Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Nanjing Medical University Affiliated Brain Hospital, No.264 Guangzhou Road, Nanjing 210029, China. Hauptthemen laut MEDLINE: Schizophrenia, Gamma Rhythm, Inhibition, Psychological, Motor Cortex. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Inhibitory control deficits are a core feature of schizophrenia, yet their spectral and temporal characteristics remain poorly defined. This study investigates fast-response inhibition in first-episode schizophrenia (FES) by focusing on low gamma-band (30–50 Hz) oscillations within the right inferior frontal gyrus (rIFG)–pre-supplementary motor area (preSMA) circuit.
Methods
We conducted a magnetoencephalography (MEG) study involving FES, their first-degree relatives (FDR), and healthy controls (HCs), examining post-stimulus low gamma (30–50 Hz) and beta-band activity across rIFG–preSMA and preSMA–lM1 circuits. Power spectral density (PSD) and functional connectivity (FC) were segmented into middle (150–250 ms) and later (250–400 ms) stages. Behavioral data (BIS-11, DSST) were integrated with MEG features in two canonical discriminant models (Model 1: multimodal; Model 2: behavior-only), with independent temporal validation.
Results
FES patients showed early low gamma power reductions in rIFG and preSMA, followed by increased rIFG–preSMA connectivity during later stages—suggesting phase-specific disruption and compensatory adaptation. Model 1 achieved 95.2% classification accuracy (80.6% cross-validated), identifying rIFG–preSMA low gamma connectivity as the strongest neural discriminator. Model 2 retained 88.5% accuracy on temporally independent samples using only BIS and DSST measures. FDR occupied an intermediate position in both models, supporting a dimensional liability continuum.
Limitations
The modest sample size, especially for the MEG recordings, may limit generalizability. Medication effects in the FES group and the cross-sectional design may also confound causal interpretation.
Conclusion
This study delineates a frequency- and phase-specific disruption in fast-response inhibition in schizophrenia, centered on rIFG–preSMA low gamma desynchronization. The identified neural and behavioral signatures support a dimensional risk framework and may inform early detection strategies in clinical and familial populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Nanjing Medical University Affiliated Brain Hospital, No.264 Guangzhou Road, Nanjing 210029, China.
- Medical School of Nanjing University, Nanjing Brain Hospital, No.22 Hankou Road, Nanjing 210093, China.
- School of Biological Sciences & Medical Engineering, Southeast University, No.2 Sipailou, Nanjing 210096, China.
- Key Laboratory of Child Development and Learning Science, Ministry of Education, Southeast University, Nanjing 210096, China.
ORCID-Profile: Zhijian Yao
Zitieren
APA
Han, Y., Du, Y., Xia, Y., Hua, L., Yao, Z., & Lu, Q. (2026). Dual-Pathway Inhibitory Dysfunction in Schizophrenia: MEG and Behavioral Markers for Risk Stratification. Journal of Psychiatry and Neuroscience. https://doi.org/10.1139/jpn-25-0109
Vancouver
Han Y, Du Y, Xia Y, Hua L, Yao Z, Lu Q. Dual-Pathway Inhibitory Dysfunction in Schizophrenia: MEG and Behavioral Markers for Risk Stratification. Journal of Psychiatry and Neuroscience. 2026. doi:10.1139/jpn-25-0109
BibTeX
@article{Han2026,
author = {Han, Yinglin and Du, Yishan and Xia, Yi and Hua, Linglin and Yao, Zhijian and Lu, Qing},
title = {Dual-Pathway Inhibitory Dysfunction in Schizophrenia: MEG and Behavioral Markers for Risk Stratification},
journal = {Journal of Psychiatry and Neuroscience},
year = {2026},
doi = {10.1139/jpn-25-0109}
}
EUVIMED